Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...
On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...
Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front payment of $925 million. Anthos was founded in 2019 by Novartis and the private equity ...
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
The FDA determined that Novo Nordisk’s obesity and diabetes drugs were no longer in short supply. Elsewhere, Concentra made a ...
Ares, CD&R and Neuberger Berman target retail apparel; Life science companies ripe for PE investment
In early January came news that Marquee Brands, which is backed by Neuberger Berman , acquired Laura Ashley, the iconic London-based brand that sells home furnishings and fashion items. The seller was ...
Blackstone (BX) intends to offload its First Eagle business for at least $4B, the Financial Times reports. The move comes as private equity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback